Silvana Aparecida Alves Corrêa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Silvana Aparecida Alves Corrêa has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ana Maria Massad Costa
Molecular Gynaecology Laboratory, Department of Gynaecology, Federal University of São Paulo, Rua Pedro de Toledo, 781 — 4th Floor, São Paulo, 04039-032 SP, Brazil
1 shared publicationCristina Valleta de Carvalho
Molecular Gynaecology Laboratory, Department of Gynaecology, Federal University of São Paulo, Rua Pedro de Toledo, 781 — 4th Floor, São Paulo, 04039-032 SP, Brazil
1 shared publicationIsmael Dale Cotrim Guerreiro da Silva
Molecular Gynaecology Laboratory, Department of Gynaecology, Federal University of São Paulo, Rua Pedro de Toledo, 781 — 4th Floor, São Paulo, 04039-032 SP, Brazil
1 shared publicationJosé Juvenal Linhares
Molecular Gynaecology Laboratory, Department of Gynaecology, Federal University of São Paulo, Rua Pedro de Toledo, 781 — 4th Floor, São Paulo, 04039-032 SP, Brazil
1 shared publicationMariano Tamura Vieira Gomes
Molecular Gynaecology Laboratory, Department of Gynaecology, Federal University of São Paulo, Rua Pedro de Toledo, 781 — 4th Floor, São Paulo, 04039-032 SP, Brazil
1 shared publication- Naiara Correia Nogueira de Souza
Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0617, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2009
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 10 (1) , 51-58
Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women
Introduction.We evaluated the association between components of the renin-angiotensin system and the development of breast cancer in a case-control study by means of angiotensin-converting enzyme (ACE) insertion/deletion (I/D) and angiotensin II type 1 (AT1)-receptor A1166C polymorphisms.Methods. Genotyping was performed by PCR-RFLP (restriction fragment length polymorphism) or PCR (polymerase chain reaction) using genomic DNA extracted from buccal cells of subjects with (101 cases) or without (307 controls) breast cancer.Results.The frequencies of genotypes for ACE were: DD, ID and II (in %: cases: 60; 20; 20; controls: 46; 37; 17; p=0.019, χ2); and for AT1receptor were:AA,AC and CC (in %: cases: 65; 30; 5; controls: 51; 44; 5; p=0.114, χ2).The results suggested that the A1166C polymorphism was not associated with breast cancer risk. On the other hand, for the ACE (I/D), there seemed to be different risks for cancer between cases and controls.Conclusions.The ID genotype was less frequently associated with the disease than were the DD or II; that is, women with the ID genotype were 3.1 times less likely to develop breast cancer than those with the other genotypes.The ID genotype might be protective against breast cancer and the ACE (I/D) polymorphism a possible target for developing genetic markers for breast cancer.
- 1 March 2009
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 10 (1) , 51-58
Open AccessAssociation between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women
Introduction.We evaluated the association between components of the renin-angiotensin system and the development of breast cancer in a case-control study by means of angiotensin-converting enzyme (ACE) insertion/deletion (I/D) and angiotensin II type 1 (AT1)-receptor A1166C polymorphisms.Methods. Genotyping was performed by PCR-RFLP (restriction fragment length polymorphism) or PCR (polymerase chain reaction) using genomic DNA extracted from buccal cells of subjects with (101 cases) or without (307 controls) breast cancer.Results.The frequencies of genotypes for ACE were: DD, ID and II (in %: cases: 60; 20; 20; controls: 46; 37; 17; p=0.019, χ2); and for AT1receptor were:AA,AC and CC (in %: cases: 65; 30; 5; controls: 51; 44; 5; p=0.114, χ2).The results suggested that the A1166C polymorphism was not associated with breast cancer risk. On the other hand, for the ACE (I/D), there seemed to be different risks for cancer between cases and controls.Conclusions.The ID genotype was less frequently associated with the disease than were the DD or II; that is, women with the ID genotype were 3.1 times less likely to develop breast cancer than those with the other genotypes.The ID genotype might be protective against breast cancer and the ACE (I/D) polymorphism a possible target for developing genetic markers for breast cancer.